Logo-apb
Adv Pharm Bull. 2024;14(3): 513-523.
doi: 10.34172/apb.2024.061
  Abstract View: 413
  PDF Download: 283

Review Article

Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities

Fereshteh Asgharzadeh 1 ORCID logo, Maryam Moradi Binabaj 2, Sahar Fanoudi 3, William C. Cho 4, Yu-jeong Yang 5, Maryam Azarian 6, Mehdi Shafiee Ardestani 7, Nasim Nasiri 8, Marzieh Ramezani Farani 5* ORCID logo, Yun Suk Huh 5* ORCID logo

1 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Department of Nutrition, Food Sciences and Clinical Biochemistry, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Science, Gonabad, Iran.
3 Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
4 Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
5 NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.
6 Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
7 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
8 Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
*Corresponding Authors: Marzieh Ramezani Farani, Email: farani.marzi@inha.ac.kr, Email: farani.marzi@gmail.com; Yun Suk Huh, Email: yunsuk.huh@inha.ac.kr

Abstract

Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 414

Your browser does not support the canvas element.


PDF Download: 283

Your browser does not support the canvas element.

Submitted: 14 May 2024
Revision: 03 Jul 2024
Accepted: 29 Jul 2024
ePublished: 31 Jul 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)